The Different Mechanisms of Cancer Drug Resistance: A Brief Review

Advanced Pharmaceutical Bulletin
Behzad MansooriBehzad Baradaran

Abstract

Anticancer drugs resistance is a complex process that arises from altering in the drug targets. Advances in the DNA microarray, proteomics technology and the development of targeted therapies provide the new strategies to overcome the drug resistance. Although a design of the new chemotherapy agents is growing quickly, effective chemotherapy agent has not been discovered against the advanced stage of cancer (such as invasion and metastasis). The cancer cell resistance against the anticancer agents can be due to many factors such as the individual's genetic differences, especially in tumoral somatic cells. Also, the cancer drug resistance is acquired, the drug resistance can be occurred by different mechanisms, including multi-drug resistance, cell death inhibiting (apoptosis suppression), altering in the drug metabolism, epigenetic and drug targets, enhancing DNA repair and gene amplification. In this review, we outlined the mechanisms of cancer drug resistance and in following, the treatment failures by common chemotherapy agents in the different type of cancers.

Citations

Mar 11, 2018·International Journal of Cancer. Journal International Du Cancer·Julia Ketteler, Diana Klein
Aug 28, 2018·Journal of Cellular Physiology·Mehri GhasabiBehzad Baradaran
Oct 27, 2018·Journal of Cellular Physiology·Khalil HajiasgharzadehBehzad Baradaran
Jan 23, 2019·Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences·Ali SaberHidde J Haisma
Feb 12, 2019·Journal of Cellular Physiology·Behzad MansooriBehzad Baradaran
Dec 28, 2018·Chembiochem : a European Journal of Chemical Biology·Marcus J C LongYimon Aye
Nov 2, 2018·Recent Patents on Anti-cancer Drug Discovery·Maricruz Anaya-RuizMartín Pérez-Santos
Jun 5, 2019·Critical Reviews in Biochemistry and Molecular Biology·Mark R Sullivan, Matthew G Vander Heiden
May 12, 2019·International Journal of Molecular Sciences·Marilina García-Aranda, Maximino Redondo
Dec 14, 2018·Anti-cancer Agents in Medicinal Chemistry·Najibeh ShekariTohid Kazemi
Jul 28, 2019·The FEBS Journal·Liang GuMandeep Kaur
Sep 5, 2019·Cells·Yujing ChiJichun Yang
Sep 5, 2019·Cells·João M A DelouHelena L Borges
Oct 9, 2019·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Hamdan S Al-MalkyAbdel-Moneim M Osman
Feb 8, 2019·Current Protein & Peptide Science·Arunaksharan NarayanankuttyVinayak Narayanankutty
Jan 16, 2020·International Journal of Molecular Sciences·Teodora CosteaMaria-Magdalena Mocanu
Nov 14, 2019·Current Pharmaceutical Design·Morteza GhandadiSorour Ashari
Jan 15, 2020·Bulletin of Mathematical Biology·Avner Friedman, Nourridine Siewe
Feb 6, 2018·Advanced Pharmaceutical Bulletin·Khalil Hajiasgharzadeh, Behzad Baradaran
Mar 4, 2020·BMC Pharmacology & Toxicology·Angelika Długosz-PokorskaAnna Janecka
Feb 20, 2020·Current Drug Metabolism·Ganji Purnachandra Nagaraju, Mohammad Amjad Kamal
Jan 7, 2020·Current Drug Metabolism·Kanisha Shah, Rakesh M Rawal
Oct 28, 2019·Mini Reviews in Medicinal Chemistry·Yutao XieYajun Cao
Apr 21, 2020·Phytotherapy Research : PTR·Saeedeh Keyvani-GhamsariAsma Gul
May 16, 2020·Journal of Cellular and Molecular Medicine·Rao Fu, Jing-Shan Tong
Jun 5, 2020·JCI Insight·Jacob J AdashekRazelle Kurzrock
Jun 11, 2020·Chemical Communications : Chem Comm·Justin DubbertJens Voskuhl
Jun 23, 2020·The Journal of Pharmacy and Pharmacology·Leila SadeghiGholamreza Dehghan
Sep 10, 2020·Signal Transduction and Targeted Therapy·Huibin SongChang Zou
Sep 26, 2020·Medical Oncology·LeeYoung Park
Feb 6, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Sraa Abu-MelhaMohamad R Abdelaziz
Apr 17, 2019·Pharmaceutical Research·Carolina SousaMafalda Videira
Oct 16, 2019·Oncology Letters·Wenfei ZhaoMiaomiao Liang
Oct 17, 2019·Nanomaterials·Jacinta Oliveira PinhoMaria Manuela Gaspar
Jan 18, 2020·Current Pharmaceutical Design·Mohammad A AnsariNiyaz Ahmad

❮ Previous
Next ❯

Datasets Mentioned

BETA
GM-CSF

Methods Mentioned

BETA
acetylation

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Related Papers

Acta científica venezolana
F ArveloC Cotte
Revista da Associação Médica Brasileira
A L Albiero, D H Pozzi
European Journal of Internal Medicine
Ernesto VinciMariano Malaguarnera
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
Jason A SprowlAlex Sparreboom
© 2022 Meta ULC. All rights reserved